Orchestra BioMed Q3 revenue beats expectations

Orchestra Biomed Holdings

10/11/2025 21:40

Overview

Orchestra BioMed Q3 revenue beats analyst expectations at $0.9 mln

Company secured $147.6 mln in proceeds from strategic transactions and equity offerings

Expanded collaborations with Medtronic and Terumo, enhancing strategic partnerships

Outlook

Company expects to complete Virtue Trial enrollment by mid-2027

Orchestra BioMed extends cash runway into Q4 2027

Company plans to complete BACKBEAT study enrollment by mid-2026

Result Drivers

STRATEGIC TRANSACTIONS - Secured $147.6 mln in proceeds from strategic transactions and equity offerings to support clinical programs

CLINICAL TRIAL PROGRESS - Initiated patient enrollments in the Virtue SAB U.S. pivotal trial, targeting mid-2027 for completion

EXPANDED COLLABORATIONS - Strengthened partnerships with Medtronic and Terumo, including a new ROFR agreement with Terumo

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$900,000
$757,600 (5 Analysts)
Q3 EPS
-$0.40
Q3 Net Income
-$20.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Orchestra Biomed Holdings Inc is $12.00, about 68.3% above its November 7 closing price of $3.81

Press Release: ID:nGNX4Y6qpg

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)